linoleic-acid and Dry-Eye-Syndromes

To study the efficacy of topical application of alpha-linolenic acid (ALA) and linoleic acid (LA) for dry eye treatment.. Formulations containing ALA, LA, combined ALA and LA, or vehicle alone, were applied to dry eyes induced in mice. Corneal fluorescein staining and the number and maturation of corneal CD11b(+) cells were determined by a masked observer in the different treatment groups. Real-time polymerase chain reaction was used to quantify expression of inflammatory cytokines in the cornea and conjunctiva.. Dry eye induction significantly increased corneal fluorescein staining; CD11b(+) cell number and major histocompatibility complex Class II expression; corneal IL-1alpha and tumor necrosis factor alpha (TNF-alpha) expression; and conjunctival IL-1alpha, TNF-alpha, interferon gamma, IL-2, IL-6, and IL-10 expression. Treatment with ALA significantly decreased corneal fluorescein staining compared with both vehicle and untreated controls. Additionally, ALA treatment was associated with a significant decrease in CD11b(+) cell number, expression of corneal IL-1alpha and TNF-alpha, and conjunctival TNF-alpha.. Topical ALA treatment led to a significant decrease in dry eye signs and inflammatory changes at both cellular and molecular levels.. Topical application of ALA omega-3 fatty acid may be a novel therapy to treat the clinical signs and inflammatory changes accompanying dry eye syndrome.

Topics: Administration, Topical; alpha-Linolenic Acid; Animals; CD11b Antigen; Cell Count; Conjunctiva; Cornea; Cytokines; Disease Models, Animal; Dry Eye Syndromes; Fluorescein; Fluorescent Antibody Technique, Indirect; Linoleic Acid; Mice; Mice, Inbred C57BL; Monocytes; Ophthalmic Solutions; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome